Predictive biological factors for late survival in patients with HER2-positive breast cancer
Abstract The human epidermal growth factor receptor-2 (HER2) enriched subtype of breast cancer is associated with early recurrence, mostly within 5 years. However, anti-HER2 therapies have improved outcomes and their benefits persist in the long term. This study aimed to determine predictive factors...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-07-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-38200-y |